Abstract: Although acupuncture analgesia has been reported in clinical trials, its mechanisms have been unclear. It was recently reported that spinal astrocytes-produced interleukin-17A (IL-17A) facilitates inflammatory pain. Hypothesizing that electroacupuncture (EA) would suppress inflammation-enhanced IL-17A synthesis to inhibit pain, we induced hyperalgesia, as measured by decreased paw withdrawal latency (PWL) to a noxious thermal stimulus, by subcutaneously injecting complete Freund's adjuvant (CFA, 0.08 ml, 40 µg Mycobacterium tuberculosis) into the hind paws of rats, or intrathecal (i.t.) IL-17A (400 ng in 10 µl) into the lumbar spinal cord. We then gave EA at acupoint GB30 for two 20-min periods, once immediately after CFA or IL-17A administration and again 2 h post-injection. For sham control, EA needles were inserted into GB30 without stimulation. PWL was measured before and 2.5 and 24 h after injection. Spinal IL-17A, IL-17 receptor A (IL-17RA), and phosphorylated NR1, an essential subunit of the N-methyl D-aspartate receptor (NMDAR), were determined 24 h post-CFA or -IL-17A using immunohistochemistry and western blot. Compared to sham control, EA inhibited CFA-caused thermal hyperalgesia 2.5 and 24 h post-CFA and concurrently suppressed inflammation-enhanced IL-17A and IL-17RA synthesis and NR1 phosphorylation in the ipsilateral spinal cord. EA inhibited IL-17A-produced thermal hyperalgesia, IL-17RA synthesis and NR1 phosphorylation. Our data suggest that EA inhibits inflammatory pain by blocking spinal IL-17A synthesis. Since previous study shows that IL-17A is located in astrocytes and IL-17RA and NR1 are in neurons, the data suggest that EA alleviates pain by modulating glia-neuronal interactions that involve IL-17A, IL-17RA, and NR1 phosphorylation.
INTRODUCTION
Spinal glia is known to be involved in transmission and modulation of noxious messages. These cells produces a number of algesic substances such as the proinflammatory cytokines interleukin 1 beta (IL-1β), tumor necrosis factor alpha (TNF-α), and IL-6 to promote spinal transmission and processing of noxious signals [1, 2] . It is reported that IL-1β is up-regulated in spinal astrocytes to increase NMDA NR1 phosphorylation, an essential subunit of the N-methyl Daspartate receptor (NMDAR), which in turn promote pain in an inflammatory pain rat model [3] [4] [5] [6] . IL-17A, recently found in astrocytes of patients with multiple sclerosis [7] , increase in concentration in the spinal cord of rats with nerve injury [8] . Further, intrathecal (i.t.) injection of IL-17A in rats induced thermal hyperalgesia and peripheral inflammation caused up-regulation of IL-17A in spinal astrocytes and IL-17 receptor A (IL-17RA) in spinal neurons [9] . These studies indicate that spinal IL-17A facilitates pain. Acupuncture has been used in China and other Asian countries for thousands of years and is an option for managing pain [10] . Although acupuncture analgesia has been reported in clinical trials [11] , its mechanisms are still unclear. Previous study shows that electroacupuncture (EA) significantly increases paw withdrawal latency (PWL) and inhibits intra-plantar CFA-induced up-regulation of glial fibrillary acidic protein, a marker of astrocytes [12] . EA also markedly inhibits intra-articular CFA-induced up-regulation of IL-1β, IL-6, and TNFα in the spinal cord [13] [14] [15] .
Such studies suggest that EA modulates astrocyte activity to inhibit pain, but whether the modality regulates IL-17A synthesis to alleviate inflammatory pain was not known. We hypothesized that EA down-regulates inflammationexaggerated spinal IL-17A and its receptors to inhibit inflammatory pain. Since IL-17A facilitates NR1 phosphorylation [9] , we also hypothesized that EA alleviates pain by inhibiting NR1 phosphorylation. These hypotheses were tested in a rat model of inflammatory pain.
MATERIALS AND METHODOLOGY Animal Preparation
Male Sprague-Dawley rats weighing 270-300 g (Harlan, Indianapolis, IN) were housed under controlled laboratory conditions. Room temperature was 22°C and humidity was 40%-60%, with 12-h light-dark cycles, food and water ad libitum. They were acclimatized to the environment for five days prior to experimentation. The animal protocols were approved by the Institutional Animal Care and Use Committee of the University of Maryland School of Medicine, Maryland, USA.
Experimental Design
Three experiments were carried out to study possible EA mechanisms on and modulation of 1) intra-plantar CFAcaused thermal hyperalgesia in three groups: CFA + EA, CFA + sham and saline + sham, and i.t. IL-17A-caused thermal hyperalgesia in three groups: IL-17A + EA, IL-17A + sham, and saline (i.t.) + sham, 2) IL-17A during CFAinduced inflammation, and 3) spinal IL-17RA and phosphorylated NR1 (p-NR1).
I.t. IL-17A Delivery
Spinal punctures were conducted as previously stated [9] . Briefly, under isoflurane anesthesia, the rat's dorsal pelvic area was disinfected with 70% alcohol. A 21-gauge sterile needle was inserted between lumbar vertebrae L5 and L6. A catheter of a PE10 polyethylene tube (Clay Adams, USA), which was pre-filled with 10 µl of 400 ng IL-17A (ProSpec, Israel) or vehicle isolated from 5 µl of saline using a small air bubble, was placed into the needle and advanced 4 cm from the tip of the needle up to the lumber enlargement, which was confirmed by a tail-twitch. The drug, or vehicle, was slowly injected and flushed with saline. Three minutes later, the catheter and the needle were respectively removed.
Induction of Hind Paw Hyperalgesia
CFA (Sigma, USA; 0.08 ml, 40 µg Mycobacterium tuberculosis), which was suspended in an 1:1 oil/saline emulsion, was injected into the plantar surface of one hind paw of the rat to result in inflammatory hyperalgesia [16] . The inflammation appeared as redness, edema, and hyperresponsiveness to noxious stimuli, and was limited to the injected paw. Hyperalgesia was assessed with PWL to a noxious heat stimulus.
Paw Withdrawal Latency
The rats in experiments 1 were tested for hind paw withdrawal latency (PWL) by a previously described method [16, 17] . They were acclimatized for 30 min under an inverted clear plastic box on the glass surface of a Paw Thermal Stimulator System (UCSD, San Diego, USA). The plantar surface of each hind paw was stimulated with a radiant heat stimulus from lamp bulb (CXL/CXR, 8 V, 50 W) underneath the glass floor. Four tests were performed with 5-min interval between each test. When hindpaw was moved away from the stimulus, PWL to the nearest 0.1 s was automatically recorded. Baseline PWL was approximately 10.0 s in naive animals. Paws were stimulated randomly to exclude order effects. A 20-s cut-off was set to avoid tissue damage.
Mean PWL was determined by calculating average of the latency of four tests. The investigator who conducted the PWL tests was blind to animal group.
Electroacupuncture
Electroacupuncture (EA) was given at acupoint GB30 as described before [19] . In humans, GB30 is found at the junction of the lateral 1/3 and medial 2/3 of the distance between the greater trochanter and the sacral hiatus. Equivalent anatomical landmarks were used to locate these points in the rat. The transposition of an acupoint from the known human map to the anatomically comparable position in animals is widely used to determine points in animals [18] [19] [20] [21] and has been demonstrated to be effective [19, 22, 23] . After cleaning the skin with alcohol swabs, one investigator swiftly inserted two #32 gauge, 0.5" acupuncture needles bilaterally into each hind limb of the rat at GB 30 while another gently held the animal. The needles were stabilized with adhesive tape [19] . EA (10 Hz, 2 mA, 0.4 ms pulse width) was delivered by a stimulator (Electrostimulator 8-C, Pantheon Research Inc) via two electrodes for two 20-min periods, once immediately after CFA or IL-17A administration and again 2 h post-CFA or post-IL-17A. A symmetrical biphasic wave was delivered to each electrode so that it was alternately positive and negative to stimulate the bilateral needles. To minimize discomfort, stimulation intensity was gradually increased over a period of 2 min to 2 mA, which we have found to be the maximum level that can be tolerated by unrestrained rats [24] . During EA treatment, each rat was placed under an inverted clear plastic chamber approximately 5" × 8" × 11" and neither restrained nor given any anesthetic. Mild muscle twitching was observed. The animals remained awake and still during treatment and gave no observable signs of distress.
For sham control, acupuncture needles were inserted bilaterally into GB30 without electrical or manual needle manipulation. Sham EA showed little anti-hyperalgesia in our previous study [19] , which makes it an appropriate control for non-specific needling effects. Sham-and EAtreated animals were handled identically. The investigators performing the behavioral tests were blind to treatment assignments.
Immunoflurescence
Rats (n=3/ group) were deeply anesthetized 24 hr post-CFA with sodium pentobarbital [60 mg/kg, intraperitoneal injection (i.p.)] and immediately perfused transcardially using 4% paraformaldehyde (Sigma) in 0.1 M phosphate buffer (PB) at pH 7.4. The lumbar 4-5 spinal cord was harvested, submerged in the fixative for another 2 h at 4 °C, and immersed in 30% sucrose (w/v) in PB saline (PBS) overnight for cryoprotection. The tissue was sectioned at 30-µm. After rinsed in PBS and blocked in PBS containing 10% normal donkey serum for 60 min, sections were incubated overnight at room temperature with rabbit polyclonal IL-17A antibody (1:50, Cat# sc-7927, Santa Cruz Biotechnology, Inc.). After three washings in PBS each for 10 min, the sections were incubated in CY2-conjugated donkey anti-rabbit (1:200, Jackson ImmunoResearch Laboratories). Control sections were similarly processed but with no primary antisera. The sections were placed on gelatin-coated slides, covered with aqueous mounting medium (Biomeda Corp., CA), and observed with a Nikon fluorescence microscope. IL-17A-immunopositive cells were magnified with a 20× objective lens and counted on 10 randomly-selected sections from each rat. Mean of IL-17A-immunopositive cell number on each section were determined for each rat and then for the group.
Western Blot
The rats (n=4/group) were anesthetized with sodium pentobarbital (60 mg/kg, i.p.) and decapitated 24 h post-CFA or -IL-17A. After a high-pressure injection of saline into the sacral spinal cord, the ipsilateral and contralateral dorsal portions of the lumbar 4-5 spinal cord were harvested. The ipsilateral spinal dorsal horn was homogenized in protein extraction buffer containing 1% EDTA and 1% Halt TM Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific, USA) and centrifuged at 14000 rpm for 10 min at 4°C. The upper portion was collected and measured with the Bio-Rad Protein Assay for protein concentration. The same quantity of protein was mixed with loading buffer, and electrophoresed on a 4-20% (w/v) SDS-PAGE and transferred onto a polyvinylidine difluoride (PVDF) membrane (Bio-Rad, USA) with a Trans-Blot Cell System (Bio-Rad). The membrane was blocked for 1 h at room temperature with 5% (w/v) milk in TBS (20 mM Tris, 150 mM NaCl, pH 7.4) containing 0.1% Tween 20 (TBST). The blocked membrane was then probed overnight at 4°C with phosphor-NR1 antiserum (Serine 896, 1:500, Cat # sc-31669-R, Santa Cruz) or IL-17RA antiserum (1:500, Cat # sc-30175, Santa Cruz). After washed with TBST buffer, the membrane was incubated for 2 h at room temperature with goat anti-rabbit horseradish peroxidase-conjugated IgG (1:2000; KPL) diluted in 5% milk in TBST buffer. The enhanced chemilluminescence detection system (ECL, Thermo Scientific) was used to detect the immunoreactivity of membrane proteins. Autoradiograms were digitized, and quantified with Scion NIH Image 1.60. The membranes were re-probed with β-actin antibody (1:5000, Sigma) as a loading control after washed in stripping buffer (Thermo Scientific) for 20 min. The investigators who harvested the spinal cord and carried out the western blot were blinded to the animal assignment.
Data Analysis
PWL data were shown in mean ± S.E.M. and analyzed using repeated measures analysis of variance (ANOVA) followed by Tukey's multiple comparisons (GraphPad Prism). Protein data were analyzed with one-way betweensubject ANOVA followed by the Tukey's multiple comparison. The statistical significance level was set at P<0.05.
RESULTS

EA Alleviated CFA-and IL-17A-Caused Thermal Hyperalgesia
Baseline PWL to noxious thermal stimuli was similar before CFA in all groups of rats. CFA injection significantly shortened ipsilateral PWL. Saline injection produced no effect on PWL (Fig. 1A) . Contralateral PWL had no changes after CFA (data not shown). Repeated-measures ANOVA revealed significant differences among the three groups of rats, respectively given CFA + EA, CFA + sham, or saline + sham at 2 and 24 h post-CFA. Tukey's multiple comparisons revealed that EA significantly (P<0.05) increased PWL of the hind paw ipsilateral to the CFA injection compared to sham control (Fig. 1A) but had no significant effect on contralateral hind paw PWL (data not shown).
I.t. IL-17A resulted in significant (P<0.05) decrease of PWL of bilateral hind paws 2-24 after its injection compared to saline injection, indicating that the IL-17A induced thermal hyperalgesia (Fig. 1B) . The mean values of bilateral PWL were presented. EA significantly increased PWL compared to sham control in IL-17A injected rats (P<0.05), suggesting that EA attenuates IL-17A-induced thermal hyperalgesia compared to sham.
EA Down-Regulated IL-17A Synthesis in Spinal Dorsal Horn Astrocytes
IL-17A-immunoreactive astrocytes mainly existed in laminae I-II and V-VI. In ipsilateral laminae I-II, IL-17A immunoreactive cells in CFA + EA rats were significantly more than those in saline control rats but significantly fewer than those in CFA + sham rats, indicating that EA suppressed CFA inflammation-caused IL-17A up-regulation in the dorsal horn. In laminae V-VI, there were significantly more ipsilateral IL-17A immunoreactive cells in rats with CFA injection than in control rats, but there was no significant difference between CFA + EA and CFA + sham rats (Fig. 2) .
EA Down-Regulated Dorsal Horn IL-17RA in CFA-and IL-17A-Injected Rats
Relative spinal IL-17RA levels were significantly (P<0.05) higher in CFA-injected rats given sham EA treatment than in saline-injected rats. This suggests that peripheral inflammation induced IL-17RA up-regulation. Spinal IL-17RA levels were significantly lower in CFAinjected rats given EA treatment than in CFA-injected rats given sham EA (P<0.05). This indicates that EA treatment significantly inhibited peripheral inflammation-induced IL-17RA up-regulation compared to sham (P<0.05; Fig. 3) . Similarly, i.t. IL-17A significantly induced up-regulation of IL-17RA and EA treatment mitigated such up-regulation compared to sham control (Fig. 4) .
EA Down-Regulated Dorsal Horn NR1 Phosphorylation in CFA-and IL-17A-Injected Rats
Spinal p-NR1 was significantly higher in CFA-injected rats given sham EA treatment than in saline-injected rats (P<0.05). This suggests that peripheral inflammation enhances NR1 phosphorylation. Spinal p-NR1 levels were significantly lower in CFA +EA than CFA+ sham EA rats (P<0.05), showing that EA treatment significantly suppressed peripheral inflammation-induced NR1 phosphorylation compared to sham EA (P<0.05; Fig. 5) . Consistently, IL-17A significantly enhanced NR1 phosphorylation and EA treatment decreased such phosphorylation (Fig. 6) .
DISCUSSION
In this study, EA significantly alleviated CFAinflammation-and IL-17A-induced thermal hyperalgesia and significantly suppressed IL-17A production in the spinal cord during inflammation. The data indicates that EA inhibits inflammatory pain by down-regulating spinal IL-17A that facilitates pain.
Opioid receptor and nociceptin/orphanin FQ (N/OFQ) peptide receptor activation might mediate EA inhibition of IL-17A. Substance P (SP), a key neuropeptide for the transmission of noxious inputs, activates glial cells during pain [25] . SP release is blocked by µ and δ opioid receptor activation [26] . EA significantly activates these receptors [16] and has been shown to inhibit a tooth pulp stimulationevoked release of immunoreactive SP [27] . Opioid receptors are found in astrocytes [28] , which suggests that opioids act directly on astrocytes to inhibit IL-17A synthesis. Taken together, these facts suggest that EA induces the release of endogenous spinal opioids that in turn inhibit cytokine synthesis in glial cells.
It has been reported that the opioid-receptor-like 1 (ORL1) are expressed on the spinal astrocytes in rats. Intrathecal administration of N/OFQ significantly downregulates CFA-injection-exaggerated spinal cord IL-1β, IL-6, and TNFα expression in the inflammatory pain rat model [29] . Such inhibitory effect was abolished by the ORL1 receptor-specific antagonist [Nphe (1) ]N/OFQ(1-13)NH2. In vitro studies with astrocyte cultures also show that N/OFQ inhibits cytokine gene expression through the ORL1 receptor [29] . Since studies suggest that EA induces release of spinal N/OFQ [30, 31] , it is plausible that EA-induced spinal N/OFQ might suppress spinal cytokine synthesis.
In this study, EA significantly mitigated CFA-and IL-17A-enhanced NR1 phosphorylation in the spinal dorsal horn. It is well known that p-NR1 modulates NMDAR activity and facilitates nociceptive input transmission in inflammatory pain models [3] [4] [5] . This suggests that inflammation-enhanced IL-17A might facilitate pain through NR1 phosphorylation, and EA might decrease spinal 
Fig. (5).
Representative Western blot (upper panel) and quantification (lower panel) of relative p-NR1 levels in CFA-injected rats; saline-injected rats were used as control (100%). Note that p-NR1 level is higher in CFA rats than in control and that EA significantly decreased p-NR1 compared to sham control. *P < .05 vs. saline-injected control and @P < .05 vs. CFA + EA (N = 4/ group). Fig. (6) . Representative Western blot (upper panel) and quantification (lower panel) of relative p-NR1 levels in IL-17A-injected rats; saline-injected rats were used as control (100%). Note that p-NR1 level is higher in IL-17A rats than in control and that EA significantly decreased p-NR1 compared to sham control. *P < .05 vs. saline-injected control and @P < .05 vs. IL-17A + EA (N = 4/ group).
IL-17A, relieving the pain by diminishing NR1 phosphorylation. A previous study demonstrated that EA inhibits bone cancer-caused IL-1β expression and bone cancer pain [24] . IL-1β also promotes NR1 phosphorylation [6] . Together, these findings suggest that EA decreases noxious input-induced NR1 phosphorylation at the spinal level to alleviate pain.
We further showed that EA down-regulates inflammation-and IL-17A-induced IL-17RA, which may be associated to EA inhibition of NR1 phosphorylation. Previous studies demonstrate that IL-17RAs are localized in NR1-containing spinal neurons [9] , and IL-17A antibodies block CFA-and IL-17A-caused IL-17RA up-regulation and NR1 phosphorylation [9] . Those data suggest that endogenous IL-17A may up-regulate IL-17RA on NR1-containing neurons to facilitate NR1 phosphorylation. Thus EA down-regulation of inflammation-induced IL-17RA contributes to EA inhibition of NR1 phosphorylation.
A recent study showed that neuronal IL-17RA mediates IL-17A-induced up-regulation of transient receptor potential vanilloid 4 (TRPV4) in DRG neurons, suggesting that IL-17A is involved in mechanical hyperalgesia [32] . It has been reported that EA increased mechanical threshold in the CFAinduced inflammatory pain model [33] . EA may modulate IL-17RA in DRG neurons to inhibit pain, which warrants further investigation.
CONCLUSION
The present study demonstrates that EA attenuates inflammatory hyperalgesia and inhibits astrocyte IL-17A, neuronal IL-17RA synthesis, and NR1 phosphorylation. The data suggest that EA alleviates pain by modulating glianeuron interaction and that IL-17A, IL-17RA, and NR1 phosphorylation are involved.
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